Everand Logo

Welcome to Everand!

  • STAT

    ‘Drug development is a long, long process’: pharma CEO in Italy sounds a note of caution on Covid-19

    "The process is very serious and long," said Massimo Scaccabarozzi of Janssen unit in Milan. For #coronavirus vaccine development, "we have to trust the scientists.”
    by Elizabeth Cooney Mar 26, 2020 2 minutes
    Medical workers tend to patients at a new intensive care unit for Covid-19 cases at the Casal Palocco hospital near Rome.

    The CEO of a global pharmaceutical company’s operations in Italy has advice for anyone expecting a Covid-19 solution anytime soon: Drugs and vaccines take time to create — and to be sure they work safely.

    “Drug development is a long, long, long process,” Massimo Scaccabarozzi, CEO of Johnson & Johnson’s Janssen unit based in Milan, said Thursday on

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
    Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
    STAT2 min readAmerican Government
    STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
    The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

    Related Books & Audiobooks